SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy for large ...

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the ...

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial We integrated data from five prospective studies of frontline ...

Brain lymphoma is a rare and aggressive disease - the mere mention of it may strike some of your deepest health fears. But why are some cases of the disease linked to the very common glandular fever, ...

Maximum tumor diameter (MTD) showed a strong association with the risk for relapse in patients with limited-stage Hodgkin lymphoma (HL) achieving PET negativity, with each centimeter increase in MTD ...

Large B-cell lymphomas (LBCL) exhibit three distinct microenvironment archetype profiles defined by specific immune and stromal cell patterns. These profiles show divergent cell-cell communication ...

Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor T-cell product (CAR T), significantly improved event-free survival (EFS), complete response (CR) rate, and ...

Research into the most prevalent tumors in developing countries significantly lags behind research into those cancers that are more common in Western countries, resulting in higher mortality rates.

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...